{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+GM-CSF+Vaccine", "query": { "intervention": "Placebo GM-CSF Vaccine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+GM-CSF+Vaccine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T01:46:45.151Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04197687", "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Multi-epitope HER2 Peptide Vaccine TPIV100", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 480, "start_date": "2020-02-20", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04197687" }, { "nct_id": "NCT00324831", "title": "GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "Intervention/procedure", "type": "PROCEDURE" }, { "name": "antibody therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" }, { "name": "colony-stimulating factor therapy", "type": "PROCEDURE" }, { "name": "cytokine therapy", "type": "PROCEDURE" }, { "name": "monoclonal antibody therapy", "type": "PROCEDURE" }, { "name": "non-specific immune-modulator therapy", "type": "PROCEDURE" }, { "name": "therapeutic procedure", "type": "PROCEDURE" }, { "name": "tumor cell derivative vaccine", "type": "PROCEDURE" }, { "name": "vaccine therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Favrille", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 2, "location_summary": "Beverly Hills, California • Chapel Hill, North Carolina", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324831" }, { "nct_id": "NCT00001090", "title": "A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "APL 400-047", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": null, "completion_date": "1999-10", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Rochester, New York + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001090" }, { "nct_id": "NCT02873819", "title": "Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "GL-0817", "type": "DRUG" }, { "name": "Hiltonol", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gliknik Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-03-30", "completion_date": "2021-05-25", "has_results": false, "last_update_posted_date": "2022-03-08", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02873819" }, { "nct_id": "NCT01989572", "title": "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Mucosal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Melanoma", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IIA Cutaneous Melanoma AJCC v6 and v7", "Stage IIA Uveal Melanoma AJCC v7", "Stage IIB Cutaneous Melanoma AJCC v6 and v7", "Stage IIB Uveal Melanoma AJCC v7", "Stage IIC Cutaneous Melanoma AJCC v6 and v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIA Uveal Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Tyrosinase Peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 815, "start_date": "2000-02-23", "completion_date": "2013-01-31", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 148, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989572" }, { "nct_id": "NCT03012100", "title": "Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bilateral Breast Carcinoma", "Breast Inflammatory Carcinoma", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma", "Unilateral Breast Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Multi-epitope Folate Receptor Alpha Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 280, "start_date": "2017-03-31", "completion_date": "2026-07-31", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012100" }, { "nct_id": "NCT02465268", "title": "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Glioblastoma", "Malignant Glioma", "Astrocytoma, Grade IV", "GBM" ], "interventions": [ { "name": "pp65-shLAMP DC with GM-CSF", "type": "BIOLOGICAL" }, { "name": "unpulsed PBMC and saline", "type": "BIOLOGICAL" }, { "name": "Td", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" }, { "name": "pp65-flLAMP DC with GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2016-08-09", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 3, "location_summary": "Gainesville, Florida • Orlando, Florida • Durham, North Carolina", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465268" }, { "nct_id": "NCT03376477", "title": "Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "GM-CSF vaccine", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Prevnar13", "type": "DRUG" }, { "name": "Placebo Prevnar13", "type": "OTHER" }, { "name": "Placebo GM-CSF Vaccine", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-09-23", "completion_date": "2025-05-30", "has_results": true, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03376477" }, { "nct_id": "NCT05163080", "title": "SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "SurVaxM", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MimiVax, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2021-11-18", "completion_date": "2024-08-18", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 11, "location_summary": "San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Summit", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05163080" }, { "nct_id": "NCT00454168", "title": "Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "PR1 leukemia peptide vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "The Vaccine Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2005-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-09-25T01:46:45.151Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "South San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00454168" } ] }